Topiramate
Sulfamate-substituted derivative of D-fructose
Also known as: Topamax · Topiragen · Epitomax · Topamac · Topimax · McN-4853 · RWJ-17021 · Topiramatum
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Alternative second line anticonvulsant | 5-10 mg/kg PO q12h | PO | q12h | — | 🌎 NA |
| Alternative treatment for refractory generalized and focal seizures | 5-10 mg/kg PO twice daily | PO | twice daily | — | 🌎 NA |
| Seizures (Initial dose) | 2-10 mg/kg PO q12h | PO | q12h | — | 🌎 NA |
| Seizures | 5-10 mg/kg PO twice daily | PO | twice daily | — | 🌎 NA |
| Refractory epilepsy | 2.5-5 mg/kg PO three times daily | PO | three times daily | — | 🌎 NA |
- Seizures: Start at the lower dosage to reduce adverse effects.
- Refractory epilepsy: Presently, the author is using this drug at this dose, but at this stage there is not enough data to know how effective this treatment will be.
Cats
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Automatisms (running fits) and focal seizure activity | 12.5-25 mg PO (total dose) q8-12h | PO | q8-12h | — | 🌎 NA |
- Automatisms (running fits) and focal seizure activity: Gradual adaptation in dosing is recommended. Inappetence is a major adverse effect with higher doses.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Topiramate is a novel, second-generation anticonvulsant medication primarily used as an add-on (adjunctive) therapy for refractory seizure disorders in dogs and cats.
- Clinical Utility: It is particularly useful for managing partial (focal) seizures and automatisms (e.g., "running fits" in cats).
- Pharmacokinetic Profile: It has a remarkably short half-life in dogs (2-4 hours), but its high affinity for brain receptors allows for sustained therapeutic activity despite rapid clearance.
- Role in Therapy: Often considered when traditional first-line therapies (like phenobarbital, potassium bromide, or levetiracetam) are insufficient to achieve seizure control.
- Practical Considerations: Generics are available, which helps mitigate costs, though the frequent dosing schedule (often TID in dogs) requires significant owner commitment.
Mechanism of action
Topiramate has a multimodal mechanism of action that dampens excitatory pathways and enhances inhibitory neurotransmission in the central nervous system:
- Voltage-gated Sodium Channels → Blocks repetitive action potentials in a time-dependent manner, preventing the spread of seizure activity.
- GABA Receptors → Increases the frequency of GABA activation at GABA_A receptors, enhancing inhibitory signals in the brain.
- AMPA/Kainate Receptors → Antagonizes these specific glutamate receptors, directly blocking excitatory neurotransmission (without affecting NMDA receptors).
- Carbonic Anhydrase → Weakly inhibits isoenzymes CA-II and CA-IV, though this is believed to play only a minor role in its overall antiepileptic efficacy.
Safety & warnings
Contraindications
- Known hypersensitivity to topiramate
Adverse effects
- GI distress (dogs)
- Inappetence (dogs, cats)
- Irritability (dogs)
- Sedation/Lethargy (cats, dogs)
- Ataxia (dogs)
- Somnolence (humans)
- Dizziness (humans)
- Acute myopia with secondary angle closure glaucoma (rare, humans)
- Calcium phosphate renal calculi (humans)
- Anorexia
- Weight loss
- Gastrointestinal upset
Precautions
Use with caution in patients with impaired hepatic or renal function. Topiramate can cause a hyperchloremic metabolic acidosis and reduce citrate excretion in the urine, increasing urine pH and leading to calcium phosphate renal calculi. It is an FDA Category C drug for pregnancy (teratogenic effects noted in mice and rats) and enters maternal milk; use with caution in nursing patients.
Drug interactions
Topiramate may increase amitriptyline levels
Concomitant use may increase the risk of renal stone formation
May exacerbate the adverse effects of topiramate
May increase topiramate levels
May decrease topiramate levels; phenytoin levels may increase
May decrease topiramate and VPA levels
May increase clearance and decrease plasma concentrations of topiramate
Monitoring
- Seizure frequency and severity (Efficacy)
- Adverse effects (GI distress, sedation, inappetence)
- Body weight and appetite
- Renal function in compromised patients
Pharmacokinetics
Half-life
Absorption
Rapidly absorbed after oral administration in dogs, but absolute bioavailability varies between 30-60%.
Distribution
High affinity for receptors in the brain allows for sustained therapeutic activity.
Metabolism
Not extensively metabolized (in humans).
Elimination
About 70% is excreted unchanged in the urine (in humans).
Overdose
Overdoses in humans have caused convulsions, drowsiness/lethargy, slurred speech, blurred and double vision, impaired mentation/stupor, ataxia, metabolic acidosis, hypotension, agitation, and abdominal pain. In dogs, common findings reported to the ASPCA APCC include ataxia and lethargy.
Treatment:
- Gut emptying protocols if the ingestion was recent.
- Supportive therapy.
- Hemodialysis is effective in enhancing the elimination of topiramate from the body.
Available products
Formulations
- Tablets
- Sprinkle capsules
- 25 mg tablet
- 50 mg tablet
- 100 mg tablet
- 200 mg tablet
- 15 mg sprinkle capsule
- 25 mg sprinkle capsule
- 50 mg sprinkle capsule
- 15 mg capsule
- 25 mg capsule
- 50 mg capsule
Human-labeled
- Topiramate Tablets: 25 mg, 50 mg & 100 mg (Topamax, Topiragen, generic)
- Topiramate Sprinkle Capsules: 15 mg & 25 mg (Topamax, generic)
- Topamax 25 mg, 50 mg, 100 mg, 200 mg tablets
- Topamax 15 mg, 25 mg, 50 mg sprinkle capsules
Regulatory status
POM (Prescription Only Medicine). Used under the prescribing cascade.
No regulatory data for: 🇺🇸 US · 🇪🇺 EU · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Tablets should be stored in tight containers at room temperature (15-30°C; 59-86°F); protect from moisture. Sprinkle capsules should be stored in tight containers at temperatures below 25°C (76°F); protect from moisture.
Client information
Important: Never stop this medication abruptly, as it can trigger severe "rebound" seizures. Always consult your veterinarian before changing the dose.
- Administration: Can be given with or without food. If your pet experiences stomach upset, try giving the medication with a small meal.
- Behavioral Changes: Watch for signs of irritability, sedation, or loss of appetite, especially when starting the medication or increasing the dose. Contact your vet if these occur.
- Seizure Diary: Keep a detailed log of any seizures (date, time, duration, and severity) to help your veterinarian determine if the medication is working.
- Commitment: Because this drug is processed very quickly in dogs, you may need to administer it 2 to 3 times a day exactly as prescribed.
- Expectations: The clinical use of this agent is relatively 'investigational' in veterinary patients, and it is often used when other medications have failed.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.